Presentation is loading. Please wait.

Presentation is loading. Please wait.

Moderate-to-severe exacerbations for patients who experienced an exacerbation in the past year Network meta-analysis results for treatments compared with.

Published byΛώτ Δάβης Modified over 5 years ago

Similar presentations

Presentation on theme: "Moderate-to-severe exacerbations for patients who experienced an exacerbation in the past year Network meta-analysis results for treatments compared with."— Presentation transcript:

1 Moderate-to-severe exacerbations for patients who experienced an exacerbation in the past year Network meta-analysis results for treatments compared with placebo. Moderate-to-severe exacerbations for patients who experienced an exacerbation in the past year Network meta-analysis results for treatments compared with placebo. The black horizontal lines represent the 95% CIs of the summary treatment effects BUDE, budesonide; FLUT, fluticasone; FORM, formoterol; INDAC, indacaterol; SALM, salmeterol; VILA, vilanterol; GLYC, glycopyrronium bromide; TIOT, tiotropium; FORM/BECLO, formoterol/beclomethasone; FORM/BUDE, formoterol/budesonide; VILA/FLUT, vilanterol/fluticasone; SALM/FLUT, salmeterol/fluticasone; TIOT/SALM, tiotropium/salmeterol; INDA/GLYC, indacaterol/glycopyrronium; TIOT/FLUT/SALM, tiotropium/fluticasone/salmeterol; TIOT/BUDE/FORM, tiotropium/budesonide/formoterol. Andrea C Tricco et al. BMJ Open 2015;5:e009183 ©2015 by British Medical Journal Publishing Group

Download ppt "Moderate-to-severe exacerbations for patients who experienced an exacerbation in the past year Network meta-analysis results for treatments compared with."

Similar presentations

SABA (short acting beta agonist) inhalers Aerosol InhalersGeneric Component No of doses Cost/ device Dosing directions Ventolin evohalerSalbutamol 100mcg/dose200£1.501-2.

SABA (short acting beta agonist) inhalers Aerosol InhalersGeneric Component No of doses Cost/ device Dosing directions Ventolin evohalerSalbutamol 100mcg/dose200£
New inhalers for COPD and asthma 2015

New inhalers for COPD and asthma 2015
Overview The Burden of COPD Main Challenges in the Diagnosis of COPD.

Overview The Burden of COPD Main Challenges in the Diagnosis of COPD.
Practical Recommendations for COPD:

Practical Recommendations for COPD:
Vitamin D3 increased ASL antimicrobial activity.

Vitamin D3 increased ASL antimicrobial activity.
 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.
Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.

Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.
What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?

What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?
Number of local authorities (LAs) commissioning each service directly or indirectly (n=148) (*Flu vaccination data excludes the service commissioned across.

Number of local authorities (LAs) commissioning each service directly or indirectly (n=148) (*Flu vaccination data excludes the service commissioned across.
Study sample selection process.

Study sample selection process.
Mean expense per year on courses and conferences that trainees have not been reimbursed. Mean expense per year on courses and conferences that trainees.

Mean expense per year on courses and conferences that trainees have not been reimbursed. Mean expense per year on courses and conferences that trainees.
Daily contribution (%) of sodium and potassium from major food groups among participants aged 8–12 years (n=517), which includes major food groups provided.

Daily contribution (%) of sodium and potassium from major food groups among participants aged 8–12 years (n=517), which includes major food groups provided.
Defining study follow-up periods—index date (entry into cohort) and breaks in MSP registration. †End of follow-up due to earliest of: active TB diagnosis,

Defining study follow-up periods—index date (entry into cohort) and breaks in MSP registration. †End of follow-up due to earliest of: active TB diagnosis,
Bar charts comparing the results of ePROMs between patients who found the scores inadequately assessed their symptoms against all other patients leaving.

Bar charts comparing the results of ePROMs between patients who found the scores inadequately assessed their symptoms against all other patients leaving.
Comorbidity status in patients with CKD stage 4 or 5 not on dialysis, peritoneal dialysis, haemodialysis and transplanted patients (bars), as well as in.

Comorbidity status in patients with CKD stage 4 or 5 not on dialysis, peritoneal dialysis, haemodialysis and transplanted patients (bars), as well as in.
Scatter graph showing total work time equivalent of all specialist palliative care practitioners commissioned by the Clinical Commissioning Group (CCG)

Scatter graph showing total work time equivalent of all specialist palliative care practitioners commissioned by the Clinical Commissioning Group (CCG)
(A) Indirectly age-sex-deprivation-ethnicity standardised procedure ratios for combined eye injection procedures (OPCS-4: C794 and C893) by CCG in England,

(A) Indirectly age-sex-deprivation-ethnicity standardised procedure ratios for combined eye injection procedures (OPCS-4: C794 and C893) by CCG in England,
DSM-IV delirium prevalence, including the estimated delirium prevalence in the 31 patients that did not undergo delirium assessment following initial screening.

DSM-IV delirium prevalence, including the estimated delirium prevalence in the 31 patients that did not undergo delirium assessment following initial screening.
Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.

Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.
A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.

A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.

Similar presentations

Ads by Google